BioCatalystWatch
AMGNWorkspace / AMGN / OverviewCompany library
Price
Market cap
Next catalystExpected Q4 2026Dazodalibep · Study completionCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

Dazodalibep

CD40L

PreINDP1P2P3FilingApproved

Dazodalibep

CD40L

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Dazodalibep

CD40L

PreINDP1P2P3FilingApproved
Upcoming / outlook

Dazodalibep

CD40L

PreINDP1P2P3FilingApproved

Other pipelines

GIPR × GLP-1R

PreINDP1P2P3FilingApproved

GIPR × GLP-1R

PreINDP1P2P3FilingApproved

PDE4

PreINDP1P2P3FilingApproved
Repatha (evolocumab)

PreINDP1P2P3FilingApproved
MariTide — MARITIME-T2D-3

GIPR × GLP-1R

PreINDP1P2P3FilingApproved

Partner / License out

IL-15

PreINDP1P2P3FilingApproved

Approved / commercial

VEGF

Approved

PreINDP1P2P3FilingApproved

PDE4

Approved

PreINDP1P2P3FilingApproved

PDE4

Approved

PreINDP1P2P3FilingApproved

DLL3 × CD3

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

Nplate (romiplostim)

Thrombopoietin receptor

Approved

PreINDP1P2P3FilingApproved
LUMAKRAS (sotorasib)

KRAS G12C

Approved

PreINDP1P2P3FilingApproved

CD19

Approved

PreINDP1P2P3FilingApproved

History / paused

LPAR1

PreINDP1P2P3FilingApproved
ABP 206

PD-1

PreINDP1P2P3FilingApproved

LPAR1

PreINDP1P2P3FilingApproved
Rocatinlimab

OX40

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

AMGN PR & News

PR & News

AMGN SEC archive